Price T Rowe Associates Inc Humacyte, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Humacyte, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 28,069 shares of HUMA stock, worth $148,204. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,069
Previous 15,853
77.06%
Holding current value
$148,204
Previous $50,000
170.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding HUMA
# of Institutions
131Shares Held
30.9MCall Options Held
323KPut Options Held
582K-
Black Rock Inc. New York, NY7.14MShares$37.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.73MShares$25 Million0.0% of portfolio
-
State Street Corp Boston, MA2.87MShares$15.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$9.83 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.6MShares$8.44 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $544M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...